{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:36:04Z","timestamp":1784054164984,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s13181-018-0659-3","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T08:47:36Z","timestamp":1524041256000},"page":"134-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances\u2014Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam\u2014in the UK"],"prefix":"10.1007","volume":"14","author":[{"given":"Rachelle","family":"Abouchedid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Gilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul I","family":"Dargan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R. H","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"659_CR1","unstructured":"United Nations Office on Drugs and Crime. The challenge of new psychoactive substances: A Report from the Global SMART Programme. 2013. Available from: http:\/\/www.unodc.org\/documents\/scientific\/NPS_2013_SMART.pdf (22 October 2016, date last accessed)."},{"key":"659_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/10826084.2013.808224","volume":"49","author":"DM Wood","year":"2014","unstructured":"Wood DM, Dargan PI. Using internet snapshot surveys to enhance our understanding of the availability of the designer psychoactive substance alpha-methyltryptamine (AMT). Subst Use & Misuse. 2014;49:7\u201312.","journal-title":"Subst Use & Misuse"},{"issue":"7","key":"659_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3109\/15563650.2014.933346","volume":"52","author":"AE Vermette-Marcotte","year":"2014","unstructured":"Vermette-Marcotte AE, Dargan PI, Archer JR, Gosselin S, Wood DM. An Internet snapshot study to compare the international availability of the designer psychoactive substance methiopropamine. Clin Toxicol (Phila). 2014;52(7):678\u201381.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"659_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s13181-014-0425-0","volume":"11","author":"H Nizar","year":"2015","unstructured":"Nizar H, Dargan PI, Wood DM. Using internet snapshot surveys to enhance our understanding of the availability of the designer psychoactive substance 4-methylaminorex and 4,4\u2032-dimethylaminorex. J Med Toxicol. 2015;11(1):80\u20134.","journal-title":"J Med Toxicol"},{"key":"659_CR5","unstructured":"Iverson L. Letter to Minister of State for crime prevention and ASB reduction: phenezepam advice. Advisory Council on the Misuse of Drugs (ACMD). 2011. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/119184\/acmd-advice-phenazepam.pdf Accessed 18 August 2016."},{"issue":"3","key":"659_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jflm.2011.12.014","volume":"19","author":"PD Maskell","year":"2012","unstructured":"Maskell PD, De Paoli G, Nitin Seetohul L, Pounder DJ. Phenazepam: the drug that came in from the cold. J Forensic Legal Med. 2012;19(3):122\u20135.","journal-title":"J Forensic Legal Med"},{"key":"659_CR7","unstructured":"Expert Committee on Drug Dependence. World Health Organisation. Etizolam. Critical review report agenda item 4.13. Thirty-ninth Meeting Geneva, 6\u201310 November 2017. http:\/\/www.who.int\/medicines\/access\/controlled-substances\/CriticalReview_Etizolam.pdf . Accessed 10 Dec 2017."},{"issue":"3","key":"659_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00228-012-1361-z","volume":"69","author":"PI Dargan","year":"2013","unstructured":"Dargan PI, Davies S, Puchnarewicz M, Johnston A, Wood DM. First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam. Eur J Clin Pharmacol. 2013;69(3):361\u20133.","journal-title":"Eur J Clin Pharmacol"},{"key":"659_CR9","unstructured":"Marcel C. Explanatory memorandum to the misuse of drugs (designation) (Amendment No. 2) (England, Wales and Scotland) Order 2012 No. 1310 and the Misuse of Drugs (Amendment no.3) (England, Wales and Scotland) Regulation 2012 No. 1311. 2012. http:\/\/www.legislation.gov.uk\/uksi\/2012\/1310\/pdfs\/uksiem_20121310_en.pdf . Accessed 20 August 2016."},{"key":"659_CR10","unstructured":"Advisory Council on the Misuse of Drugs. Misuse of Drugs Act 197. 1971 c. 38. http:\/\/www.legislation.gov.uk\/ukpga\/1971\/38\/contents . Accessed 1 December 2017."},{"key":"659_CR11","unstructured":"Expert Committee on Drug Dependence. World Health Organisation. Phenazepam pre-review report agenda item 5.8. Thirty-seventh meeting. Geneva, 16\u201320 November 2015. http:\/\/www.who.int\/medicines\/access\/controlled-substances\/5.8_Phenazepam_PreRev.pdf Accessed 16 August 2016."},{"key":"659_CR12","unstructured":"EMCDDA. EMCDDA\u2013Europol 2013 Annual report on the implementation of council decision 2005\/387\/JHA. 2013. Available from: http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_229598_EN_TDAN14001ENN.pdf Accessed 16 August 2016."},{"key":"659_CR13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1021\/jm00197a021","volume":"22","author":"JB Hester","year":"1979","unstructured":"Hester JB, Von Voigtlander P. 6-Aryl-4H-s-triazolo[4,3-a][1,4]-benzodiazepines. Influence of 1-substitution on pharmacological activity. J Med Chem. 1979;22:1390\u20138.","journal-title":"J Med Chem"},{"key":"659_CR14","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1021\/jo01058a010","volume":"27","author":"LH Sternbach","year":"1962","unstructured":"Sternbach LH, Fryer RI, Metlesics W, Reeder E, Sach G, Saucy G, et al. Quinazolines and 1,4-benzodiazepines. VI.1a halo-, methyl-, and methoxy-substituted 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones1b,c. J Org Chem. 1962;27:3788\u201396.","journal-title":"J Org Chem"},{"key":"659_CR15","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1021\/jo01058a009","volume":"27","author":"LH Sternbach","year":"1962","unstructured":"Sternbach LH, Fryer RI, Metlesics W, Sach G, Stempel A. Quinazolines and 1,4-benzodiazepines. V. O-aminobenzophenones. J. Org. Chem. 1962;27:3781\u20138.","journal-title":"J. Org. Chem."},{"issue":"11","key":"659_CR16","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/jms.3279","volume":"48","author":"B Moosmann","year":"2013","unstructured":"Moosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, Auw\u00e4rter V, et al. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom. 2013;48(11):1150\u20139.","journal-title":"J Mass Spectrom"},{"issue":"2","key":"659_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11419-013-0187-4","volume":"31","author":"B Moosmann","year":"2013","unstructured":"Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingsh\u00f6fer L, Auw\u00e4rter V. Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol. 2013;31(2):263\u201371.","journal-title":"Forensic Toxicol"},{"issue":"7\u20138","key":"659_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/dta.1628","volume":"6","author":"B Moosmann","year":"2014","unstructured":"Moosmann B, Bisel P, Auw\u00e4rter V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal. 2014;6(7\u20138):757\u201363.","journal-title":"Drug Test Anal"},{"key":"659_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3109\/10826080903443628","volume":"45","author":"J Hillebrand","year":"2010","unstructured":"Hillebrand J, Olszewski D, Sedefov R. Legal highs on the Internet. Subst Use Misuse. 2010;45:330\u201340.","journal-title":"Subst Use Misuse"},{"key":"659_CR20","unstructured":"EMCCDA. Online sales of new psychoactive substances\/\u2018legal highs\u2019: Summary of results from the 2011 multilingual snapshots (Briefing paper). 2012. http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_143801_EN_SnapshotSummary.pdf Accessed 22 October 2016."},{"key":"659_CR21","unstructured":"EMCDDA. EMCDDA-Europol 2012 Annual report on the implementation of Council Decision 2005\/387\/JHA, 2012. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/734\/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf Accessed 1 December 2017."},{"key":"659_CR22","unstructured":"Home Office. Guidance. List of most commonly encountered drugs currently controlled under the misuse of drugs legislation. Updated 1 June 2017. https:\/\/www.gov.uk\/government\/publications\/controlled-drugs-list--2\/list-of-most-commonly-encountered-drugs-currently-controlled-under-the-misuse-of-drugs-legislation . Accessed 26 November 2017."},{"issue":"2","key":"659_CR23","first-page":"155","volume":"3","author":"S Nyol","year":"2013","unstructured":"Nyol S, Gupta M. Immediate drug release dosage form: a review. J Drug Deliv Ther. 2013;3(2):155\u201361.","journal-title":"J Drug Deliv Ther"},{"key":"659_CR24","unstructured":"Erowid, LSD Blotter Art gallery. https:\/\/www.erowid.org\/chemicals\/lsd\/lsd_images_gallery1.shtml Accessed 28 November 2017."},{"key":"659_CR25","unstructured":"European Commission. Budget. INFOREURO http:\/\/ec.europa.eu\/budget\/contracts_grants\/info_contracts\/inforeuro\/inforeuro_en.cfm . Accessed 1 March 2016 and 25 November 2014."},{"key":"659_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2012.07.011","volume":"39","author":"P Deluca","year":"2012","unstructured":"Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Holmefjord Flesland L, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;39:221\u20136.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"659_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237\u201346.","journal-title":"Am J Eval"},{"key":"659_CR28","unstructured":"National Health Service Research Authority. UK policy framework for health and social care research. V3.3. 7\/11\/2017. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/uk-policy-framework-health-social-care-research\/ Accessed 26 November 2017."},{"key":"659_CR29","unstructured":"Ford C, Law F. Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice 2014. https:\/\/smmgp.org.uk\/media\/11962\/guidance025.pdf Accessed 25 October 2016."},{"key":"659_CR30","unstructured":"Reed K, Bond A, Witton J, Cornish R, Hickman M, Strang J. The changing use of prescribed benzodiazepines and z-drugs and of over-the-counter codeine-containing products in England: a structured review of published English and international evidence and available data to inform consideration of the extent of dependence and harm. King\u2019s College London. 2011. https:\/\/www.kcl.ac.uk\/ioppn\/depts\/addictions\/research\/drugs\/benzodiazepinesz-drugsandcodeineproducts.aspx Accessed 25 October 2016."},{"key":"659_CR31","unstructured":"Public Health England. Adult substance misuse statistics from the National Drug Treatment Monitoring System (NDTMS). 1 April 2016 to 31 March 2017. https:\/\/www.ndtms.net\/Publications\/downloads\/Adult%20Substance%20Misuse\/Adult-statistics-from-the-national-drug-treatment-monitoring-system-2016-17.pdf . Accessed 1 December 2017."},{"key":"659_CR32","unstructured":"Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2016 registrations. Deaths related to drug poisoning in England and Wales from 1993 onwards, by cause of death, sex, age and substances involved in the death. Release date 2\/08\/2017. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2016registrations . Accessed 1 December 2017."},{"key":"659_CR33","unstructured":"EMCDDA. EMCDDA\u2013Europol joint report on a new psychoactive substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (\u2018MT-45\u2019). 2014. http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_230615_EN_TDAS14007ENN.pdf Accessed 16 August 2016."},{"key":"659_CR34","first-page":"365","volume":"52","author":"F Grossenbacher","year":"2014","unstructured":"Grossenbacher F, Souille J, Djerrada Z, Passouant O, Gibaja V. Exposure to 5f-P22, 5 IAI and diclazepam: a case report. Clin Toxicol. 2014;52:365.","journal-title":"Clin Toxicol"},{"key":"659_CR35","unstructured":"Advisory Council on the Misuse of Drugs. Part of: Drug misuse and dependency Advice on U-47,700, etizolam and other designer benzodiazepines. Published: 20 December 2016 https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/579352\/ACMD_TCDO_Report_U47700_and_Etizolam_and_designer_benzodiazepines.pdf Accessed 1 December 2017."},{"issue":"4","key":"659_CR36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1467-842X.2002.tb00185.x","volume":"26","author":"JRM Caplehorn","year":"2002","unstructured":"Caplehorn JRM, Drumger OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002;26(4):358\u201362.","journal-title":"Aust N Z J Public Health"},{"key":"659_CR37","unstructured":"Winstock A. The Global Drug Survey 2014 findings. 2014. http:\/\/www.globaldrugsurvey.com\/facts-figures\/the-global-drug-survey-2014-findings\/ Accessed 1 November 2016."},{"key":"659_CR38","unstructured":"Hibell B, Guttormsson U, Ahlstr\u00f6m S, Balakireva O, Bjarnason T, Kokkevi A et al. The 2011 European School Survey Project on Alcohol and Other Drugs (ESPAD) report. Substance use among students in 36 European countries. 2011. http:\/\/www.espad.org\/Uploads\/ESPAD_reports\/2011\/The_2011_ESPAD_Report_FULL_2012_10_29.pdf Accessed 15 June 2016."},{"key":"659_CR39","doi-asserted-by":"crossref","unstructured":"The ESPAD Group. ESPAD Report 2015. Results from the European School Survey Project on Alcohol and Other Drugs. http:\/\/www.espad.org\/sites\/espad.org\/files\/TD0116477ENN_002.pdf Accessed 1 December 2017.","DOI":"10.1007\/978-94-007-0753-5_941"},{"key":"659_CR40","unstructured":"Bluelight.org (RC\u2019s) 2\u2032-chlorodiazepam (diclazepam) brand new benzo RC. 2014. http:\/\/www.bluelight.org\/vb\/threads\/685248-2-chlorodiazepam-(diclazepam)-brand-new-benzo-RC\/page17 . Accessed 12 October 2016."},{"key":"659_CR41","unstructured":"Bluelight.org . Flubromazepam. 2012. http:\/\/www.bluelight.org\/vb\/threads\/654337-Flubromazepam Accessed 13 October 2016."},{"key":"659_CR42","unstructured":"Drugs-forum.com . Drug info\u2014pyrazolam drug info. 2012. https:\/\/drugs-forum.com\/forum\/showthread.php?t=190434 . Accessed 5 October 2016."},{"key":"659_CR43","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2017), European drug report 2017: trends and developments, Publications Office of the European Union, Luxembourg. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/4541\/TDAT17001ENN.pdf Accessed 1 December 2017."},{"key":"659_CR44","unstructured":"Broadfield D, Marshall J. Home Office. Seizures of drugs in England and Wales, financial year ending 2017 Statistical Bulletin 22\/17. November 2017. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/657872\/seizures-drugs-mar2017-hosb2217.pdf Accessed 1 December 2017."},{"key":"659_CR45","unstructured":"Drugs-forum.com . Drug info\u2014diclazepam drug info. 2013. Available from: https:\/\/drugs-forum.com\/forum\/showthread.php?t=221967&page=2 Accessed 8 October 2016."},{"key":"659_CR46","unstructured":"Bluelight.org . Thread: pyrazolam megathread http:\/\/www.bluelight.org\/vb\/threads\/633714-Pyrazolam-Megathread Accessed 13 October 2016."},{"key":"659_CR47","unstructured":"Bluelight.org . Thread: clonazepam as prescribed, Etiz & Flubro as occasional alternative? 2012. http:\/\/www.bluelight.org\/vb\/threads\/741567-Clonazepam-as-prescribed-Etiz-amp-Flubro-as-occasional-alternative Accessed 13 October 2016."},{"issue":"Suppl 1","key":"659_CR48","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.1111\/j.1365-2125.1981.tb01833.x","volume":"11","author":"DJ Greenblatt","year":"1981","unstructured":"Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol. 1981;11(Suppl 1):11S\u20136S.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"659_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF03189565","volume":"7","author":"VP Zherdev","year":"1982","unstructured":"Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Eur J Drug Metab Pharmacokinet. 1982;7(3):191\u20136.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"659_CR50","unstructured":"EMCDDA (2016). European drug report 2016. Trends and Developments, Publications Office of the European Union, Luxembourg http:\/\/wwwemcddaeuropaeu\/system\/files\/publications\/2637\/TDAT16001ENNpdf Accessed 29 November 2017."},{"key":"659_CR51","unstructured":"EMCDDA (2016) The internet and drug markets, EMCDDA Insights 21, Publications Office of the European Union, Luxembourg. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2155\/TDXD16001ENN_FINAL.pdf Accessed 2nd March 2018."}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-018-0659-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-018-0659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-018-0659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:09:33Z","timestamp":1571184573000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-018-0659-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1007\/s13181-018-0659-3","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"4 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}